H.C. Wainwright initiated coverage on Zevra Therapeutics with a new price target
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00